Natamycin

Polyene Antimicrobial — ALIMENTARY TRACT AND METABOLISM

Key facts

Natamycin is an ofp drug in the Polyene Antimicrobial class catalogued in DrugCentral. It was first approved by the FDA in 1978. Recorded indications include Fungal Blepharitis, Fungal conjunctivitis and Fungal keratitis.

• Approval status: ofp (first approved 1978 by the FDA).
• Drug class: Polyene Antimicrobial.
• Indications: Fungal Blepharitis, Fungal conjunctivitis and Fungal keratitis.
• ATC code: A01AB10 (Antiinfectives and antiseptics for local oral treatment).
• Molecular formula: C33H47NO13; molecular weight 665.73 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Fungal Blepharitis
• Fungal conjunctivitis
• Fungal keratitis

Mechanism & targets

• Established pharmacologic class: Polyene Antimicrobial

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1978-10-30	FDA	—	ALCON

ATC classification

ATC code	Therapeutic hierarchy
A01AB10	ALIMENTARY TRACT AND METABOLISM › STOMATOLOGICAL PREPARATIONS › STOMATOLOGICAL PREPARATIONS › Antiinfectives and antiseptics for local oral treatment
A07AA03	ALIMENTARY TRACT AND METABOLISM › ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS › INTESTINAL ANTIINFECTIVES › Antibiotics
D01AA02	DERMATOLOGICALS › ANTIFUNGALS FOR DERMATOLOGICAL USE › ANTIFUNGALS FOR TOPICAL USE › Antibiotics
G01AA02	GENITO URINARY SYSTEM AND SEX HORMONES › GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS › ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS › Antibiotics
S01AA10	SENSORY ORGANS › OPHTHALMOLOGICALS › ANTIINFECTIVES › Antibiotics

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Persistent genital arousal disorder	169.3
Appendicolith	137.0
Blood phosphorus increased	111.9
Appendicitis	110.8
Myasthenia gravis	102.3
Ventricular fibrillation	95.6
Blood uric acid increased	89.0
Hyperphosphataemia	88.9
Corneal perforation	85.6
Hypophosphataemia	77.6

Chemical structure

• Molecular formula: C₃₃H₄₇NO₁₃
• Molecular weight: 665.73 g/mol
• CAS number: —
• InChIKey: NCXMLFZGDNKEPB-FFPOYIOWSA-N
• PubChem CID: 5284447

C[C@H]1O[C@@H](O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Natamycin used for?

DrugCentral lists the following indications for Natamycin: Fungal Blepharitis, Fungal conjunctivitis and Fungal keratitis.

When was Natamycin first approved?

Natamycin was first approved by the FDA in 1978.

What drug class does Natamycin belong to?

Natamycin is in the Polyene Antimicrobial class.

What is the chemical formula of Natamycin?

Natamycin has the molecular formula C33H47NO13 and a molecular weight of 665.73 g/mol.

Sources

• DrugCentral drug card 1885 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1200656 — compound record and bioactivity
• PubChem CID 5284447 — chemical identifiers
• DrugBank DB00826 — drug record
• FDA UNII 8O0C852CPO — substance identity
• DailyMed: FDA labels for Natamycin — current prescribing information (label search)
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.